Skip to main content
. 2019 Nov;7(22):666. doi: 10.21037/atm.2019.10.22

Figure 1.

Figure 1

Prognostic impact of sPCR (A) and tPCR (B) on disease-free survival (DFS). The DFS was 71.7% in the supraclavicular pCR group and 54.1% in the non-supraclavicular pCR group. PCR also predicted a better DFS in patients who had obtained a pCR in all of the breast axillary and supraclavicular (tpCR) sites when compared with those with one or more of the three sites without pCR (non-tpCR).